Prolistem - New Azoospermia Treatment

Messages like this truly warm our hearts. ❤️

Sometimes, we don’t even know about the success stories happening after Prolistem treatment until a message like this reaches us.

Knowing that our work has helped bring hope to a family, and contributed to the journey toward welcoming a child, means more to us than words can express.

Thank you for sharing your stories with us. Every success gives us even more motivation to keep going. 🙏
***mia

Prolistem Treatment Pathway for Non-Obstructive Azoos***mia

Ask these important questions about your azoos***mia:

• What type of azoos***mia do I have?
• What is the likely cause?
• What do my FSH, LH and testosterone levels tell me?
• Do I need genetic testing?
• What are my chances of finding s***m?
• Should I prepare before microTESE?
• Are there options I should consider before surgery?

Azoos***mia is complex. Understanding your individual case is the first step toward choosing the right strategy.

At Prolistem, we are happy to discuss your case and help guide you through your journey

Can the temporary reduction in testosterone with Prolistem cause side effects?

This is one of the most common questions we receive.

The answer begins with understanding where testosterone works.

Most of the testosterone in the body circulates in the bloodstream. However, inside the te**is, testosterone levels are naturally much higher and play a key role in regulating the environment surrounding the s***m-producing stem cells.

During Phase 1, Prolistem is designed to induce a temporary and controlled reduction in intratesticular testosterone—not complete testosterone suppression. This modest change is intended to help “reset” the signaling environment within the seminiferous tubules, particularly the activity of Sertoli cells, which support s***m development.

Why is this important?

Research has shown that carefully reducing intratesticular testosterone for a limited period can stimulate biological pathways involved in s***matogonial stem cell activation and regeneration. This concept has also been explored in experimental studies investigating the recovery of s***matogenesis.

In our clinical experience, this temporary reduction has been well tolerated, and testosterone levels are restored during Phase 2, when the focus shifts to supporting s***m maturation.

At Prolistem, every step of the treatment strategy has a purpose—because improving the testicular environment comes before improving the chances of finding s***m.

How does Prolistem support men with azoos***mia?

Prolistem is designed to help improve the biological environment inside the te**es—an environment largely regulated by Sertoli cells.

Sertoli cells are often called the “nurse cells” of s***matogenesis because they protect, nourish, and support germ cells throughout their development into mature s***m.

In our research, we observed that s***matogonial stem cells obtained from men with azoos***mia were still able to survive and grow when placed in a more supportive environment outside the te**es. This suggests that, in some patients, the stem cells may retain developmental potential, while the surrounding testicular environment—particularly Sertoli-cell support—may be impaired.

This finding supports Prolistem’s strategy: rather than focusing only on the germ cells, the program aims to support and improve the Sertoli-cell-controlled environment required for s***m development.

Prolistem targets the environment that supports s***matogenesis—helping create better conditions for s***m production before microTESE.

Results may vary between patients. Prolistem is intended for selected men with non-obstructive azoos***mia under medical supervision.

Are you suffering from azoos***mia?

Not all azoos***mia is the same.

Prolistem® is specifically developed for men with non-obstructive azoos***mia (NOA), also known as primary testicular failure.

Our primary goal is to increase the chances of successful s***m retrieval during microTESE in carefully selected patients.

Clinical experience has also shown that approximately 15% of treated patients may have s***m detected in their ej*****te, potentially avoiding the need for surgical s***m retrieval.

Every patient is unique, and proper diagnosis and evaluation by a fertility specialist are essential to determine the most appropriate treatment strategy.

***mia

How to Make Sure Your Prolistem is 100% Original
Your health and journey are too important to risk on counterfeit products. To ensure you are getting the genuine, scientifically formulated Prolistem, always verify your purchase using our official channels.
Here is how you can guarantee your Prolistem is the real deal:
Buy Directly from the Source: The safest way to purchase is through our only official website: prolistem.com.
Check Our Authorized Partners: We work with a select network of trusted distributors. You can find the fully updated list of official distributors directly on our website’s dedicated page.
Verify with Us Directly: If you have already purchased a box or are unsure about a seller, we are here to help. Reach out to our team to verify authenticity before you start your regimen:
Phone: +1 646 833 9791
Email: [email protected]

New Clinical Data Presented at ESHRE 2026

We are pleased to share new clinical data presented at the ESHRE 2026 Annual Meeting evaluating the effect of Prolistem in men with non-obstructive azoos***mia (NOA) who had previously undergone two unsuccessful microTESE procedures.

In this retrospective clinical study conducted at Momart IVF Center (Turkey):

29 men with NOA and a history of repeated failed microTESE received Prolistem treatment.

After treatment, 3 of 29 patients (10.3%) had s***m detected in their ej*****te.

Among the remaining patients, 13 underwent a repeat (third) microTESE, and 3 patients (23.1%) achieved successful s***m retrieval.

Overall, s***m became available for assisted reproduction in 6 patients, with three ongoing pregnancies reported during follow-up and no treatment-related adverse events observed.

These findings are encouraging because they suggest that a subset of men who had previously failed two microTESE procedures may still achieve s***m retrieval following Prolistem treatment. While the study is retrospective and relatively small, its results are consistent with previous clinical experience evaluating Prolistem in carefully selected men with non-obstructive azoos***mia.

We thank the investigators at Momart IVF Center for their valuable contribution to advancing research in male infertility and look forward to additional prospective studies that will further define which patients are most likely to benefit from this approach.

***mia

Another wonderful day at ESHRE 2026!

It’s a pleasure connecting with fertility specialists, researchers, and partners from around the world, sharing ideas and discussing new opportunities for men with non-obstructive azoos***mia.